Results 61 to 70 of about 53,685 (285)

A phase I study to evaluate the effect of high-dose carbidopa on levodopa pharmacokinetics

Frontiers in Pharmacology
Levodopa is the gold standard treatment for Parkinson’s disease. However, a high unmet medical need exists for longer-lasting oral levodopa formulations to achieve sustained motor improvement with reduced risk of the effect wearing off.
Akane Hayashi, Atsushi Hosomi, Shinsaku Kihara, Masato Nishi, Saori Torisawa, Yoshiumi Ouchi, Hidenori Takada, Junichi Enokizono   +7 more
doaj   +1 more source

Entacapone potentiates the long-duration response but does not normalize levodopa-induced molecular changes

Neurobiology of Disease, 2008
Coadministration of entacapone with levodopa attenuates motor complications in experimental models of Parkinson's disease. The mechanisms underlying entacapone effects are unknown. We investigated the effect of entacapone, on: long-duration response (LDR)
C. Marin, E. Aguilar, G. Mengod, R. Cortés, M.C. Rodríguez-Oroz, J.A. Obeso   +5 more
doaj   +1 more source

Rasagiline as Adjunct to Levodopa for Treatment of Parkinson’s Disease: A Systematic Review and Meta-Analysis

Parkinson's Disease, 2022
Background. Rasagiline is a selective, irreversible monoamine oxidase type B inhibitor used as monotherapy in early Parkinson’s disease and as an adjunct therapy to levodopa in Parkinson’s disease with motor fluctuations. Objectives.
Osamu Kano, Hiroshi Tsuda, Ayako Hayashi, Masaki Arai   +3 more
doaj   +1 more source

Continuous Subcutaneous Foslevodopa/Foscarbidopa in Advanced Parkinson's Disease. [PDF]

Mov Disord Clin Pract
Abstract Background Continuous subcutaneous foslevodopa/foscarbidopa (LDp/CDp) provides 24‐h delivery of levodopa‐carbidopa prodrugs for advanced Parkinson's disease. Real‐world 1‐year European data remain limited. Objectives To characterize 1‐year changes in motor, non‐motor, autonomic, quality‐of‐life and sleep outcomes, and in concomitant therapy ...
Hero M, Grozdanić N, Andrić RB, Papić E, Perković O, Vuletić V.   +5 more
europepmc   +2 more sources

NMDAR‐antibody encephalitis: Seizure semiology and EEG findings

Epileptic Disorders, EarlyView.
Abstract Background N‐methyl‐D‐aspartate receptor antibody encephalitis (NMDAR‐Ab‐E) is an autoantibody‐mediated disorder, characterized by acute development of neuropsychiatric symptoms, seizures, movement disorders, and autonomic instability. Objectives To describe acute seizure semiology and electroencephalogram (EEG) findings in patients with a ...
Maria Emilia C. Andraus, Bernard Liem, Sidra Aurangzeb, Mkael Symmonds, Adam E. Handel, Sarosh R. Irani, Arjune Sen   +6 more
wiley   +1 more source

Comparative adsorption of levodopa from aqueous solution on different activated carbons [PDF]

, 2009
Adsorption on activated carbon has been successfully used in wastewater and drinking water treatment plants for the removal of various pollutants. Among them, pharmaceutical compounds have become a growing issue. The present study has focused on levodopa
Quesada-Peñate, Isariebel, Wilhelm, Anne-Marie, Julcour-Lebigue, Carine, Jáuregui Haza, Ulises Javier, Delmas, Henri, Isariebel Quesada-Peñate, Henri Delmas, Anne-Marie Wilhelm, Carine Julcour-Lebigue, Ulises-Javier Jáuregui-Haza   +9 more
core   +1 more source

Genetic developmental and epileptic encephalopathies in adulthood: Gaps in evidence and care

Epilepsia Open, EarlyView.
Abstract Developmental and epileptic encephalopathies (DEEs) are a heterogeneous group of the most severe epilepsies, characterized by seizure onset and neurodevelopmental delay in infancy or childhood, often with additional neurological and systemic comorbidities.
Alex M. Dudley, Peter Widdess‐Walsh, Christine Linehan, Danielle M. Andrade, Norman Delanty, Patrick B. Moloney   +5 more
wiley   +1 more source

Implantable electrochemical sensors for continuous blood monitoring

FlexMat, EarlyView.
Implantable electrochemical sensors enable direct, in situ, and continuous blood monitoring, shifting diagnosis from population‐based averages to dynamic, individualized analysis. This review systematically examines the influence of the unique blood properties on sensor design.
Kuangyi Zou, Yuanzhen Wang, Haidong Wang, Ye Zhang   +3 more
wiley   +1 more source

Extended-release oral capsule of carbidopa–levodopa in Parkinson disease

Therapeutic Advances in Neurological Disorders, 2018
Motor fluctuations complicate the treatment of patients with Parkinson’s disease receiving levodopa. Extended-release carbidopa–levodopa has a pharmacokinetic profile that provides a more continuous levodopa serum concentration.
Jason Margolesky, Carlos Singer
doaj   +1 more source

Somatic cell reprogramming for Parkinson's disease treatment

Ibrain, Volume 11, Issue 1, Page 59-73, Spring 2025.
The fundamental purpose of cell reprogramming to treat Parkinson's disease is to generate dopaminergic neurons (DAN) and do transplantation. There are two ways to accomplish this. One method is to induce cells into induced DA neurons (iDAN) directly or to induce cells into induced pluripotent stem cells and ultimately into iDAN in vitro. Another option
Xiaozhuo Li, Kevin Fang, Fengping Wang
wiley   +1 more source